AI Article Synopsis
- Prostate-specific antigen (PSA) levels are traditionally used to monitor prostate cancer (PCa) progression, but they may not always accurately indicate early relapse.
- PET/CT imaging using prostate-specific membrane antigen (PSMA) ligands has demonstrated high effectiveness in identifying metastatic PCa lesions and evaluating treatment responses.
- The study highlights the potential of PSMA PET/CT for early relapse detection in hormone-sensitive metastatic PCa treated with chemotherapy (docetaxel), suggesting it should complement PSA monitoring for better detection of low-volume disease.
Article Abstract
Prostate cancer (PCa) treatment monitoring usually relies on prostate-specific antigen to detect disease progression or relapse. PET/CT with prostate-specific membrane antigen (PSMA) ligands has shown high accuracy in detecting metastatic PCa lesions and could help assess response to therapy. We describe herein the early relapse detection of a hormone-sensitive metastatic upfront PCa treated with docetaxel on Ga-PSMA-11 PET/CT before biochemical progression. PSMA PET/CT should be considered to monitor PCa response to chemotherapy to detect early relapse, regardless of prostate-specific antigen levels, increasing the chances of finding low-volume oligoprogressive disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000002799 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!